In this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company, specialized in the development of Antibody-drug Conjugates.
Antibody-drug Conjugates, also known as ADCs, are a novel type of targeted anticancer agents. Today 4 drugs in this class of drugs have been approved by regulators around the world, but there are more than 150 investigational agents in this class of drugs in development.
The antibody used in an Antibody-drug Conjugate or ADC specifically target cancer cells. This approach offers various advantages over current therapies based on standard chemotherapeutic drugs currently used in the treatment of cancer. Among these advantages is that the drug kills cancer cells, but does not harm healthy cells.
In today’s episode Hofland talks with Johnson about the manufacturing of ADCs, including the complexities of the typical supply chain.
This interview was originally recorded during CPhI worldwide, the pharmaceutical industry meeting, held October 9 – 11, 2018 in Madrid, Spain. This edition was a co-production with ADC Review | the Journal of Antibody-drug Conjugates (www.adcreview.com ) and OncoZine (www.oncozine.com )
